U.S. markets close in 1 hour 36 minutes

JanOne Inc. (JAN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
4.1500-1.2400 (-23.01%)
As of 2:24PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close5.3900
Open4.6600
Bid4.1500 x 1100
Ask4.1600 x 800
Day's Range4.0500 - 5.2000
52 Week Range2.0000 - 9.2400
Volume697,099
Avg. Volume147,831
Market Cap8.273M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-3.9520
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications
    PR Newswire

    JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications

    JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has entered into an agreement with CATO SMS, a world-leading, international regulatory and clinical contract research organization (CRO). CATO SMS will assist JanOne in expanding its current FDA authorized Investigational New Drug (IND) for JAN101, an oral, sustained release formulation of sodium nitrite, to treat vascular complications to potentially restore endothelial cell function in COVID-19 patients. In addition, JAN101 is expected to enter Phase 2b trials in early 2021 to treat Peripheral Artery Disease (PAD).

  • JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101
    PR Newswire

    JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101

    JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential treatment Peripheral Artery Disease (PAD). The name change will be effective immediately and will be used in all its current and future clinical trials, Indications for a New Drug, clinical and research studies planned to be conducted in the future.

  • JanOne bolsters its scientific advisory board with two leaders in the medical field for vascular regeneration and interventional pain
    PR Newswire

    JanOne bolsters its scientific advisory board with two leaders in the medical field for vascular regeneration and interventional pain

    JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addictive pain-relieving properties has added two members to its impressive scientific advisory board. John Cooke, MD, PhD will contribute his esteemed depth of vascular expertise to help guide the success of our clinical therapeutic for the treatment of PAD. Alan Kaye, MD, PhD, is an internationally renowned anesthesiologist and pharmacologist whose pain management research and clinical formulation expertise will play a critical role in advancing our efforts to bring non-addictive pain solutions to market.